Genedata AG's Refiner MS Used by Max Planck Institute will Demo at Metabolomics Conference 2010
"Refiner MS addresses key requirements of our metabolomic plant and medical research: accuracy and quality of peak selection; ability to handle very large datasets greater than 1000 chromotagrams; easy-to-use workflows; and advanced reporting capabilities," noted Prof. Lothar Willmitzer, Institute Director at the Max Planck Institute. "Additionally, Refiner MS is uniquely visual and intuitive. It delivers huge amounts of data in three-dimensional color-coded plots enabling our biologists and chemists to identify trends and patterns. You can't understand data by looking at numbers - you need graphical representation and Refiner MS does this quite nicely."
Automated Quality Assessment and Pre-processing of Raw Data from MS Refiner MS is integral to the Genedata Expressionist enterprise system, which is built on a highly scalable architecture to provide a single-point-of-access for experimental, proprietary and public data. Compatible with instrumentation from Agilent, Applied Biosystems, Bruker, Cyphergen, Thermo Scientific, and Waters, Refiner MS provides comprehensive pre-processing tools, which help researchers extract quantified and matched peak information from raw MS data. It addresses a range of applications and set-ups from simple one-dimensional spectra to complex experiments involving labeled and label-free technologies in proteomics, metabolomics, and lipidomics.
The new Refiner MS features direct search engine integration from within workflows for interactive searches with Mascot, ChemSpider, and HMDB, as well as offline import results from Mascot, SEQUEST, and MetaboCard -- without information loss. It removes all limitations from the MS data analysis process allowing researchers to process thousands of samples and terabytes of raw MS data. Combining novel visualization for real-time interactive data quality assessment, Refiner MS uses sophisticated algorithms for intensity and alignment correction, peak detection, quantification, and matching. Its advanced raw data visualizer enables significantly faster renderings, automatic m/z peak position labeling, display of 2D peak bounds in chromatogram cuts, and shared selections between peak clusters and annotation tables.
"Our products reflect the collaborative relationships we have with our customers and we are innovating solutions such as the Refiner MS module of our Genedata Expressionist system to continually address customer requirements," noted Dr. Othmar Pfannes, CEO of Genedata. "We understand that our customers need to make sense of gigabytes of data per sample, and the refined and optimized levels of visualization and interactivity in Refiner MS enable them to explore data and extract meaningful information that paves the way for new scientific discoveries. We believe Genedata Expressionist sets the standard for omics data analysis and management."
About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world's top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, and Genedata Analyst™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Germany, Japan, and the US. www.genedata.com
Contacts
Allison Kurz Genedata Marketing & Communications Phone: +41 61 511 8459 communications@genedata.com
Jackie Thrasivoulos Genedata Public Relations Phone: +1 508 881 3109 jackie.thrasivoulos@genedata.com
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.